ESMO Breast 2020 | PHranceSCa: evaluating patient satisfaction with subcutaneous pertuzumab and trastuzumab treatment

Evandro de Azambuja, MD, PhD of the Institut Jules Bordet, Brussels, Belgium, evaluates the results of the PHranceSCa study (NCT03674112), which aimed to determine patient satisfaction with subcutaneous administration of a fixed-dose combination of pertuzumab and trastuzumab in comparison to intravenous infusion in HER2+ early breast cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).